Education
About Us
Working with TipRanks
Follow Us
Rani Therapeutics Holdings (RANI)
NASDAQ:RANI
RESEARCH TOOLSreports
RANI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.24 - $8.75
Previous CloseN/A
Volume228.85K
Average Volume (3M)337.54K
Market Cap
$88.80M
Enterprise Value$67.77M
Total Cash (Recent Filing)$6.36M
Total Debt (Recent Filing)$30.10M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
May 07, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding33,311,543
10 Day Avg. Volume97,137
30 Day Avg. Volume337,544
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-82.44
Enterprise Value/Ebitda-1.39
Forecast
1Y Price Target
$10.00Price Target Upside580.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Rani Therapeutics Holdings News
PremiumCompany Announcements
Rani Therapeutics Advances in Biotherapeutics Market
---
Bulls Say, Bears Say
Bulls Say
Market OpportunityRani is an undervalued oral play in the multi-billion dollar obesity market, offering a high-return potential.
PartnershipsRani's partnership with ProGen enables multiple obesity programs, positioning the company for significant economic benefits in key markets.
Technological InnovationRaniPill's oral delivery of semaglutide demonstrated comparable bioavailability and weight loss to subcutaneous WEGOVY, with the convenience of once-weekly administration.
Bears Say
Clinical RisksRisks include negative Phase 2 data and failure to achieve approvals for key pipeline projects, which could impact future growth.
Market UptakeSlower-than-projected market uptake poses a risk to Rani's future success in a highly competitive obesity market.
Pipeline ChallengesNegative clinical readouts with other candidates could hinder Rani's development progress and affect stock performance.
---
Options Prices
Currently, No data available
---
Ownership Overview
29.74% Insiders
2.75% Mutual Funds
5.81% Other Institutional Investors
59.62% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
The estimated number of people who visited one or more of the websites owned by Rani Therapeutics Holdings
Desktop Users
Mobile Users
RANI FAQ
What was Rani Therapeutics Holdings’s price range in the past 12 months?
Rani Therapeutics Holdings lowest stock price was $1.24 and its highest was $8.75 in the past 12 months.
What is Rani Therapeutics Holdings’s market cap?
Rani Therapeutics Holdings’s market cap is $88.80M.
When is Rani Therapeutics Holdings’s upcoming earnings report date?
Rani Therapeutics Holdings’s upcoming earnings report date is May 07, 2025 which is in 42 days.
How were Rani Therapeutics Holdings’s earnings last quarter?
Currently, no data Available
Is Rani Therapeutics Holdings overvalued?
According to Wall Street analysts Rani Therapeutics Holdings’s price is currently Undervalued.
Does Rani Therapeutics Holdings pay dividends?
Rani Therapeutics Holdings does not currently pay dividends.
What is Rani Therapeutics Holdings’s EPS estimate?
Rani Therapeutics Holdings’s EPS estimate is -0.25.
How many shares outstanding does Rani Therapeutics Holdings have?
Rani Therapeutics Holdings has 33,311,543 shares outstanding.
What happened to Rani Therapeutics Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rani Therapeutics Holdings?
Currently, no hedge funds are holding shares in RANI
---
Rani Therapeutics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (580.27% Upside)
$10.00 (580.27% Upside)
Insider Transactions
Bought Shares
Worth $30.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.90%
12-Months-Change
Fundamentals
Return on Equity
-272.52%
Trailing 12-Months
Asset Growth
-38.19%
Trailing 12-Months
Company Description
Rani Therapeutics Holdings
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
---
RANI Stock 12 Month Forecast
Average Price Target
$10.00
▲(580.27% Upside)
Technical Analysis
Verastem
―
Arcturus Therapeutics
―
Oramed Pharm
―
XTL Biopharmaceuticals Ltd. Sponsored ADR
―
PAVmed
―
Best Analysts Covering RANI
1 Year
1 Year Success Rate
3/19 ratings generated profit
1 Year Average Return
-33.78%
reiterated a buy rating 2 months ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 15.79% of your transactions generating a profit, with an average return of -33.78% per trade.
---